

References

L-32

1. ClinicalTrials.gov. U.S. National Institutes of Health. Serologic markers for inflammatory bowel disease during clinical forms with weak or strong evolution capacities. ClinicalTrials.gov Identifier:NCT01216514.
2. Bhullar M, Macrae F, Brown G, et al. Prediction of Crohn's disease aggression through NOD2/CARD15 gene sequencing in an Australian cohort. *World J Gastroenterol*. 2014;20(17):5008–5016.
3. Walsham N, Sherwood R. Fecal calprotectin in inflammatory bowel disease. *Clin Exp Gastroenterol*. 2016;9:21–29.
4. National Institute for Health and Care Excellence. Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease. December 2017. Accessed January 30, 2018.
5. Diagnosing and Managing IBD. Crohn's & Colitis Foundation of America. April 2017. Accessed January 30, 2018.
6. Rogler G, Biedermann L. Clinical utility of biomarkers in IBD. *Current Gastroenterology Reports*. 2015;17(7):26. Accessed January 30, 2018.
7. Menees S, Powell C, Kurlander J, Goel A, Chey W. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. *The American Journal Of Gastroenterology*. 2015;110(3):444-454. Accessed January 30, 2018.
8. Holtman G, Lisman-van Leeuwen Y, Berger M, et al. Diagnostic accuracy of fecal calprotectin for pediatric Inflammatory Bowel Disease in primary care: A prospective cohort study. *Annals Of Family Medicine*. 2016;14(5):437-445. Accessed January 30, 2018.
9. Fecal Calprotectin Assay for Monitoring Disease Activity in Crohn Disease. Hayes. July 7, 2017. Website accessed January 26, 2018. Accessed January 26, 2018.
10. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: management of Crohn's disease in adults. *Am J Gastroenterol*. 2018;113(4):481-517. Accessed January 16, 2019.
11. National Institute for Health and Care Excellence (NICE). Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel DG11. 2013. Accessed January 16, 2019.
12. Lasson A, Ohman L, Stotzer PO, et al. Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study. *United European Gastroenterol J*. 2015;3(1):72-79. Accessed January 16, 2019.
13. Heida A, Park KT, van Rheenen PF. Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: A systematic review and practical guide. *Inflamm Bowel Dis*. 2017;23(6):894-902. Accessed January 16, 2019.
14. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn's disease (CALM): A multicentre, randomised, controlled phase 3 trial. *Lancet*. 23 2018;390(10114):2779-2789. Accessed January 16, 2019.

15. Naismith GD, Smith LA, Barry SJ, et al. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease. *J Crohns Colitis*. 2014;8(9): 1022-9. Accessed February 26, 2019.
16. Rokkas T, Portincasa P, Koutroubakis IE. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: A diagnostic accuracy meta-analysis. *J Gastrointestin Live Dis*. 2018;27(3):299-306. Accessed February 26, 2019.
17. Wright EK, Kamm MA, De Cruz, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. *Gastroenterology*. 2015;148(5):938-947. Accessed February 26, 2019.